The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://shaunalywf247346.wikipublicity.com/7796517/retatrutide_vs_tirzepatide_a_comparative_analysis